Yuichi Iwaki
Founder at MEDICINOVA, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Yuichi Iwaki is the founder of MediciNova, Inc. (founded in 2000) where he currently holds the title of President, Chief Executive Officer & Director.
He is also currently the Chief Executive Officer at Avigen, Inc. since 1994, the Director-Transplantation Immunology at the University of South Carolina School of Medicine since 1992, and a Professor at the University of Southern California.
Previously, he served as the Chairman & Acting Chief Executive Officer at AMCOL International Corp., a Director at Antyra, Inc., and a Professor at the University of Pittsburgh School of Medicine from 1989 to 1991.
Dr. Iwaki obtained his doctorate degree from Sapporo Medical University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MEDICINOVA, INC.
2.23% | 2024-01-08 | 1,091,933 ( 2.23% ) | 2 M $ | 2024-03-30 |
Yuichi Iwaki active positions
| Companies | Position | Start |
|---|---|---|
| MEDICINOVA, INC. | Founder | 2000-09-25 |
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Chief Executive Officer | 2009-12-17 |
| University of South Carolina School of Medicine | Corporate Officer/Principal | 1991-12-31 |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | - |
Former positions of Yuichi Iwaki
| Companies | Position | End |
|---|---|---|
| University of Pittsburgh School of Medicine | Corporate Officer/Principal | 1990-12-31 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Director/Board Member | - |
| AMCOL INTERNATIONAL CORPORATION | Chairman | - |
Training of Yuichi Iwaki
| Sapporo Medical University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEDICINOVA, INC. | Health Technology |
| Private companies | 3 |
|---|---|
AMCOL International Corp.
 AMCOL International Corp. Construction MaterialsNon-Energy Minerals AMCOL International Corp. produces value-added, specialty minerals, and related product. The company was founded on December 30, 1959 and is headquartered in Hoffman Estates, IL. | Non-Energy Minerals |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
- Stock Market
- Insiders
- Yuichi Iwaki
